Manufactures and sells ceramic sanitaryware (toilets, washbasins) and faucetware (taps, mixers) under the core Cera brand, with FY26 revenue of ₹2,050.12 crore. Sanitaryware and faucetware are the lead segments, guided at 12% and 18% growth respectively for FY27, with March price hikes of 4% and 11% taken to offset brass cost inflation. Two newer brands sit in the investment phase: Senator runs 40 flagship retail stores (target 60 by FY27) and Polipluz runs 102 distributors with 1,120 dealers in plumbing (target 200 distributors and 2,000 dealers by FY27); together the two brands generated ₹19 crore in FY26 with an FY27 target of ₹70-80 crore. Tiles and construction chemicals are guided at ₹250 crore FY27 contribution, with sales expected to pick up as Morbi gas disruptions normalise. Operations run across 2 plants and 33 offices with 5,340 employees; faucetware capacity is being debottlenecked from 4.3 lakh to 5 lakh pieces per month by Q4 FY27, and a greenfield Phase 1 is budgeted at ₹150 crore. The FY26 cost structure is dominated by other operating expenses (23.6% of revenue), employee cost (12.7%) and materials (13.0%); brass is the input most exposed to spikes. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Sanitaryware, Faucetware, Senator, Polipluz, Tiles and construction chemicals. Multi-brand building materials (sanitaryware, faucetware, plumbing distribution, tiles) with own manufacturing and expanding branded retail.
| ₹ crore · consolidated | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 1,224 | 1,446 | 1,804 | 1,879 | 1,926 |
| EBITDA (ex other income) | 158 | 223 | 288 | 302 | 298 |
| margin % | 12.9 | 15.4 | 16.0 | 16.1 | 15.5 |
| Owners' profit | 101 | 151 | 209 | 239 | 246 |
| EPS, as reported (₹) | 77.48 | 116.18 | 161.01 | 183.76 | 190.40 |
| ROE % · ROCE % | 11.3 · 14.3 | 14.9 · 17.7 | 17.8 · 22.7 | 17.8 · 22.2 | 18.2 · 21.3 |
| Debt / equity (x) | 0.08 | 0.03 | 0.02 | 0.02 | 0.01 |
| Cash from operations | 268 | 98 | 162 | 236 | 122 |
| Capex | (14) | (20) | (39) | (64) | (29) |
| ₹ crore | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 464 | 439 | 549 | 401 | 493 | 452 | 581 | 422 |
| Profit before tax | 77 | 66 | 99 | 64 | 77 | 61 | 109 | 62 |
| Net profit | 57 | 52 | 76 | 47 | 69 | 46 | 86 | 47 |
| EPS (₹) | 43.75 | 39.12 | 57.62 | 36.18 | 52.37 | 35.52 | 66.39 | 36.10 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| CERA SANITARYWARE LTD ◆ | 7,184 | 29.3 | 5.25 | 20.0 | 18.2 | 20.8 | 9.5 | 17.3 |
| HINDWARE HME INOVATON LTD | 1,492 | — | 2.00 | 12.0 | (5.3) | (0.7) | 7.2 | 8.7 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 29.3 | 25.4 | 113 of 205 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 10 Sept 2026 · Newspaper ad on special window for re-lodging share transfer deeds | compliance | minimal | — | — |
| 28 Aug 2026 · CARE reaffirms AA Stable rating on Rs 100 cr bank facilities | credit debt | medium | — | — |
| 12 Aug 2026 · Cera Sanitaryware Q1 FY27: Revenue up 19.5%, margin dips on one-time costs | investor communications | medium | — | — |
| 8 Aug 2026 · Audio recording of Q1 FY2027 earnings call now available | investor communications | low | — | — |
| 8 Aug 2026 · Cera Sanitaryware Q1 FY27 results published in newspapers | compliance | minimal | — | — |
| 7 Aug 2026 · CERA Q1 FY27: Revenue up 19.5%, margins under pressure, FY27 guidance maintained | investor communications | medium | — | — |
| 7 Aug 2026 · Q1 FY27 results: Revenue up about 19.5%, PAT marginally lower | results | high | — | — |
| 7 Aug 2026 · Cera Sanitaryware Q1 FY27 results: revenue up 19%, PAT flat | results | high | — | — |
| 6 Aug 2026 · Analyst/Investor meeting scheduled for 13 August 2026 | board shareholder meetings | low | — | — |
| 27 Jul 2026 · Cera Sanitaryware Q1 FY27 Earnings Call Scheduled for August 8 | board shareholder meetings | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 45% |
| P/B | 5.3 | 2.4 | 145 of 189 | 23% |
| ROCE | 20.8 | 7.0 | 38 of 224 | 83% |
| ROE | 18.2 | 5.8 | 33 of 199 | 84% |
| Debt / Equity | 0.0 | 0.1 | 53 of 200 | 74% |
| EBITDA margin | 17.4 | 9.3 | 48 of 193 | 76% |
| Revenue growth | 5.4 | 16.4 | 122 of 189 | 36% |
| Profit growth | (0.9) | 16.8 | 105 of 183 | 43% |
| Market cap | 7184 | 230 | 33 of 227 | 86% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
